Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by serendipidyon Jan 04, 2019 3:59pm

242 Views

Post# 29188099

RE:RE:This is just the start! we will see 30-40c very soon!!

do your due dilligdnce, or are you too much of an idiot yourself? Ive read each and every case study, for each phase, studied Dr. Salzman, watched the you tube videos, studied GW pharma, taljed to the CEO, studied cbds, what have you done? Im nit pumping, im gere until it gets bought out by a pharma company.

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?